Benzinga
Benzinga
Benzinga
samedi, septembre 12

Alnylam Pharmaceuticals Inc

ALNYNASDAQ
Trade with Public
Trade with Public
$248.68
1.170.47%
À la clôture: Sep 11, 5:00 PM EST
$250.00
1.320.53%
Après les heures: Sep 11, 6:41 PM EST
AperçuActualitésPrévisions de résultatsÉvénementsObjectifs de coursDonnées financièresSentimentActionnariatComparerOptionsRapport sur les stocks

Alnylam Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Alnylam Pharmaceuticals (ALNY).

Price Target Range — 7 Quarters

Analyst Consensus — 22 Analysts

1S.Buy
19Buy
2Hold
Consensus RatingBuy# Analysts22Avg. Consensus PT$419Upside to Avg. PT+67.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →
DateFirmAnalystActionRating ChangePrice Target
Sep 8, 2026JefferiesFaisal KhurshidPT RaiseHold$230→$260
Sep 2, 2026HC Wainwright & Co.Patrick R. TrucchioMaintainedBuy$455
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $455 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and maintains $455 price target.
Benzinga Newsdesk

This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Check out opinions and coverage on Benzinga.
Avi Kapoor

PRO
BMO Capital Initiates Coverage On Alnylam Pharmaceuticals with Outperform Rating, Announces Price Target of $318

BMO Capital analyst David Lebowitz initiates coverage on Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Outperform rating and announces Price Target of $318.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $256

Wells Fargo analyst Derek Archila maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Equal-Weight and lowers the price target from $316 to $256.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $315

Truist Securities analyst Danielle Brill maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $410 to $315.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $455

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $485 to $455.
Benzinga Newsdesk

Données et API: API Benzinga · API d'actualités boursières · API de notations d'analystes · API de logo d'entreprise

Données de marché fournies par API Benzinga

Benzinga

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL

© 2026 Benzinga | All Rights Reserved